Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

In this article, we will take a look at the 12 Major Stocks to Buy According to Billionaires. The U.S. stock market had one of the worst starts, at least the worst start to a presidency since 1928.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.